1. Home
  2. Analysis
  3. Firazyr
  4. Rabeprazole

Firazyr and Rabeprazole drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Firazyr (icatibant acetate) and Rabeprazole (rabeprazole sodium). Common drug interactions include hereditary angioedema among females and laryngeal oedema among males.

The phase IV clinical study analyzes what interactions people have when they take Firazyr and Rabeprazole. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Firazyr?

Firazyr has active ingredients of icatibant acetate. eHealthMe is studying from 5,650 Firazyr users. Check the latest studies of Firazyr.

What is Rabeprazole?

Rabeprazole has active ingredients of rabeprazole sodium. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 31,689 Rabeprazole users. Check the latest studies of Rabeprazole.

On Jul, 12, 2026

13 people who take Firazyr and Rabeprazole together, and have interactions are studied.

Firazyr and Rabeprazole drug interactions.

What are the common drug interactions of Firazyr and Rabeprazole, by gender? *:

female:

  1. Hereditary angioedema (recurrent episodes of severe swelling)
  2. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  3. Lymphocyte count decreased
  4. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  5. Poor venous access
  6. Rectocele (a bulging of the front wall of the rectum into the back wall of the vagina)
  7. Urinary tract infection
  8. Heart rate decreased
  9. Impaired gastric emptying
  10. Neoplasm malignant (cancer tumour)

male:

  1. Laryngeal oedema (swelling of larynx)

What are the common drug interactions of Firazyr and Rabeprazole, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Hereditary angioedema (recurrent episodes of severe swelling)
  2. Impaired gastric emptying

50-59:

n/a

60+:

  1. Hereditary angioedema (recurrent episodes of severe swelling)
  2. Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
  3. Lymphocyte count decreased
  4. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  5. Poor venous access
  6. Rectocele (a bulging of the front wall of the rectum into the back wall of the vagina)
  7. Urinary tract infection
  8. Heart rate decreased
  9. Neoplasm malignant (cancer tumour)
  10. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)

What are the existing conditions these people have? *

  1. Hereditary Angioedema (recurrent episodes of severe swelling): 7 people, 53.85%
  2. Immune System Disorder: 3 people, 23.08%

* Approximation only. Some reports may have incomplete information.

Do you take Firazyr and Rabeprazole?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Firazyr and Rabeprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Firazyr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Rabeprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Firazyr and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rabeprazole and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on icatibant acetate and rabeprazole sodium (the active ingredients of Firazyr and Rabeprazole, respectively), and Firazyr and Rabeprazole (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.